Content about Neuropathy

July 23, 2012

A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

NEW YORK — A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

The drug maker announced Monday the results of study A0081104 of Lyrica (pregabalin), which compared the drug with placebo in healthy males to assess its effects on sperm production. The phase-4 study was required by the Food and Drug Administration.

July 5, 2012

The Food and Drug Administration has approved Lupin Pharmaceuticals' generic version of a drug used to treat pain and seizure disorders.

BALTIMORE — The Food and Drug Administration has approved Lupin Pharmaceuticals' generic version of a drug used to treat pain and seizure disorders.

Lupin announced the approval of pregabalin capsules in the 25-mg, 50-mg, 75-mg, 100-mg, 150-mg, 200-mg, 225-mg and 300-mg strengths. The drug is used to treat fibromyalgia, partial-onset seizures in adults, neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia.

June 21, 2012

The Food and Drug Administration has approved a new indication for a Pfizer drug.

NEW YORK — The Food and Drug Administration has approved a new indication for a Pfizer drug.

Lyrica (pregabalin) capsules CV now can be used for the management of neuropathic pain associated with spinal cord injury. The drug received a priority review designation for this new indication as more than 100,000 patients — approximately 40% of the 270,000 patients with spinal cord injury in the United States — suffer from this chronic, complex pain condition.

March 9, 2012

A Food and Drug Administration panel will meet Monday to discuss a class of drugs designed to treat chronic painful conditions that currently are under development and the safety issues possibly related to the drugs.

WASHINGTON — A Food and Drug Administration panel will meet Monday to discuss a class of drugs designed to treat chronic painful conditions that currently are under development and the safety issues possibly related to the drugs.

December 15, 2011

A Food and Drug Administration expert panel will review a drug made by NeurogesX as a potential treatment for pain associated with HIV.

SAM MATEO, Calif. — A Food and Drug Administration expert panel will review a drug made by NeurogesX as a potential treatment for pain associated with HIV.

NeurogesX said Thursday that the FDA Anesthetic and Analgesic Drug Products Advisory Committee would meet on Feb. 9, 2012, to review the patch drug Qutenza (capsaicin) as a treatment for pain associated with HIV-associated peripheral neuropathy, or HIV-PN.

The drug currently is approved for treating pain associated with postherpetic neuralgia.

October 31, 2011

A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.

TITUSVILLE, N.J. — A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.

June 17, 2011

Nipro Diagnostics and NeuroMetrix have teamed up to market a point-of-care test that is designed to evaluate such systemic neuropathies as diabetic peripheral neuropathy.

WALTHAM, Mass. — Nipro Diagnostics and NeuroMetrix have teamed up to market a point-of-care test that is designed to evaluate such systemic neuropathies as diabetic peripheral neuropathy.

Nipro and NeuroMetrix said the NC-stat DPNCheck test, developed by NeuroMetrix, could offer a cost-effective approach to detecting and monitoring DPN, which affects more than half of people with diabetes and could lead to such conditions as foot ulcers and limb amputation.

The companies currently are evaluating opportunities for the NC-stat DPNCheck in retail medical clinics.

November 29, 2010

A generic drug maker announced that the Food and Drug Administration has granted tentative approval for its version of a popular antidepressant.

MUMBAI, India — A generic drug maker announced that the Food and Drug Administration has granted tentative approval for its version of a popular antidepressant.

Sun Pharmaceutical Industries said the FDA approved its duloxetine hydrochloride delayed-release capsules in 20-mg, 30-mg and 60-mg strengths. The capsules are a generic version of Eli Lilly's Cymbalta, which is indicated to treat major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain.

November 4, 2010

The Food and Drug Administration has approved a new usage for a drug used to...

INDIANAPOLIS The Food and Drug Administration has approved a new usage for a drug used to treat depression and pain.

Eli Lilly said Thursday that the FDA had approved Cymbalta (duloxetine hydrochloride) for treating chronic musculoskeletal pain. This is the fifth indication for which the agency has approved Cymbalta, after major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia, Lilly said.

October 17, 2010

A company that develops drugs for pain is hoping to get approval of one of...

SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.

August 19, 2010

A Food and Drug Administration advisory committee has voted to recommend expanding the use of...

BETHESDA, Md. A Food and Drug Administration advisory committee has voted to recommend expanding the use of an Eli Lilly & Co. pain drug, the drug maker said Thursday.

Lilly said the FDA’s Anesthetic and Life Support Drugs Advisory Committee voted to recommend approval of Cymbalta (duloxetine hydrochloride) as a treatment for chronic lower back pain, though it did not support the drug as a treatment for chronic pain due to osteoarthritis. The drug currently is approved for treating diabetic peripheral neuropathic pain and fibromyalgia.

July 19, 2010

Drug maker Pfizer is suspending some clinical studies of a biotech drug for treating pain...

June 6, 2010

As more baby boomers approach their senior years—the oldest of the baby boomers turn 64...

February 21, 2010

A hypothetical company that develops a drug for treating diabetes-related nerve damage that has disease-modifying...